Cocrystal Pharma's CFO will present a company update at NobleCon 21 on December 3, 2025, in Boca Raton, Florida.
Quiver AI Summary
Cocrystal Pharma, Inc. announced that James Martin, CFO and co-CEO, will present a company overview and update on clinical progress at the NobleCon 21 conference on December 3, 2025, at 10:00 am Eastern time in Boca Raton, Florida. Investors and guests can attend at a discounted rate by registering with a provided discount code. A video of the presentation will be accessible on Cocrystal's website the following day and archived for 90 days. Cocrystal Pharma focuses on developing innovative antiviral treatments for various diseases using advanced technologies and prestigious expertise.
Potential Positives
- James Martin, CFO and co-CEO, will share a Company overview and clinical progress update at a reputable investment conference, increasing visibility among potential investors.
- Attendance at the conference is open to interested investors at a discounted rate, encouraging greater participation and engagement with the company's offerings.
- A video webcast of the presentation will be made available, extending the reach of the company's message and allowing investors who cannot attend in person to engage with the content.
- Cocrystal Pharma is positioned as a clinical-stage biotechnology company focusing on innovative antiviral treatments, highlighting its commitment to addressing significant unmet medical needs.
Potential Negatives
- The press release does not provide any new or substantial information regarding Cocrystal Pharma's clinical progress or financial status, potentially leading to investor disappointment.
- Highlighting participation in a smaller conference such as NobleCon may signal a lack of interest or visibility in larger industry events, which could raise concerns about the company's market presence.
- The mention of a discounted rate for attendance may imply financial constraints that could affect investor confidence in the company's ability to attract a broad audience or significant investment interest.
FAQ
What is the date and time of Cocrystal's presentation at NobleCon 21?
Cocrystal's presentation will be on December 3, 2025, at 10:00 am Eastern time.
Where is the NobleCon 21 conference being held?
The conference is held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida.
How can investors attend Cocrystal's presentation?
Interested investors can attend at a discounted rate by registering with the code COCPNOBLECON.
Will there be a recording of the presentation available?
Yes, a video webcast will be available on December 4, 2025, and archived for 90 days.
What type of company is Cocrystal Pharma?
Cocrystal Pharma is a clinical-stage biotechnology company developing innovative antiviral treatments for diseases like influenza and COVID.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$COCP Insider Trading Activity
$COCP insiders have traded $COCP stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $COCP stock by insiders over the last 6 months:
- PHILLIP MD ET AL FROST has made 3 purchases buying 24,000 shares for an estimated $22,787 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$COCP Hedge Fund Activity
We have seen 7 institutional investors add shares of $COCP stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 40,619 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $50,773
- NEUBERGER BERMAN GROUP LLC added 31,886 shares (+inf%) to their portfolio in Q3 2025, for an estimated $39,857
- UBS GROUP AG removed 21,344 shares (-97.4%) from their portfolio in Q3 2025, for an estimated $26,680
- JANE STREET GROUP, LLC added 21,044 shares (+inf%) to their portfolio in Q3 2025, for an estimated $26,305
- DIMENSIONAL FUND ADVISORS LP removed 14,092 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $17,615
- CITADEL ADVISORS LLC removed 10,034 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $14,950
- RENAISSANCE TECHNOLOGIES LLC added 2,900 shares (+2.3%) to their portfolio in Q3 2025, for an estimated $3,625
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$COCP Analyst Ratings
Wall Street analysts have issued reports on $COCP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/20/2025
To track analyst ratings and price targets for $COCP, check out Quiver Quantitative's $COCP forecast page.
Full Release
BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21 st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern time. The conference is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida.
Interested investors and guests of Cocrystal Pharma are welcome to attend the conference at a discounted rate. Please register here using the discount code COCPNOBLECON.
A video webcast of the Cocrystal presentation will be available on December 4, one day after the live event, on the Company's website and archived for 90 days.
About Noble Capital Markets, Inc.
Noble Capital Markets
is a research-driven investment bank that has supported small and microcap companies since 1984. As a FINRA and SEC licensed broker dealer, Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2018, Noble launched
Channelchek
—an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer investors free institutional-quality research without a subscription.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that addresses significant unmet needs by developing innovative antiviral treatments for challenging diseases including influenza, viral gastroenteritis, COVID, and hepatitis. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
[email protected]
# # #
